Seelos Therapeutics, Inc. has ongoing preclinical programs, including SLS-004, SLS-006, and SLS-007. It has filed a voluntary petition under chapter 11 of Title 11 of the United States Code in the United States Bankruptcy Court for the Southern District of New York.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume

Delayed Quote OTC Markets

More quotes

Income Statement and Estimates

More financial data

Annual profits - Rate of surprise

Company calendar

Delayed OTC Markets Other stock markets 20:25:32 01/06/2026 +04			5-day change	1st Jan Change
0.000100 ^USD	+9,900.00%		-.--%	-

12-29	Motion for Asset Sale Approved for Seelos Therapeutics, Inc.	CI
21/10/25	GLD Partners, LP acquired Select assets from Seelos Therapeutics, Inc. (OTCPK : SEEL.Q).	CI

Market Cap	101K 88.59K 81.7K 75.59K 143K 9.67M 146K 978K 384K 4.75M 380K 372K 16.44M	P/E 2022	-0.98x	P/E 2023	-0.18x
Enterprise Value	11.33M 9.91M 9.14M 8.46M 16.06M 1.08B 16.32M 109M 42.92M 531M 42.55M 41.63M 1.84B	EV / Sales 2022	-	EV / Sales 2023	11,278,456x
Free-Float	89.34%	Yield 2022 *	-	Yield 2023	-

12-29	Motion for Asset Sale Approved for Seelos Therapeutics, Inc.	CI
21/10/25	GLD Partners, LP acquired Select assets from Seelos Therapeutics, Inc. (OTCPK : SEEL.Q).	CI
14/10/25	Motion for Asset Sale Approved for Seelos Therapeutics, Inc.	CI
15/08/25	Bidding Procedure Approved for Seelos Therapeutics, Inc.	CI
01/05/25	Motion for Asset Sale Filed by Seelos Therapeutics, Inc.	CI
30/04/25	Motion for Case Conversion or Dismissal Filed for Seelos Therapeutics, Inc.	CI
16/11/24	Seelos Therapeutics, Inc. Filed for Bankruptcy	CI
18/10/24	Seelos Therapeutics, Inc.(OTCPK:SEEL) dropped from S&P TMI Index	CI
15/10/24	Top Midday Decliners	MT
15/10/24	Seelos Therapeutics, Inc.(OTCPK:SEEL) dropped from NASDAQ Composite Index	CI
27/09/24	Top Midday Decliners	MT
25/09/24	Seelos Therapeutics, Inc. Announces the Signing of A Material Transfer Agreement with the U.S. Army Medical Materiel Development Activity	CI
25/09/24	Sector Update: Health Care Stocks Mixed Late Afternoon	MT

21/09/23	Benchmark Cuts Price Target on Seelos Therapeutics to $1 From $4, Maintains Speculative Buy Rating	MT
21/09/23	Guggenheim Downgrades Seelos Therapeutics to Neutral From Buy	MT
21/09/23	Cantor Fitzgerald Downgrades Seelos Therapeutics to Neutral From Overweight	MT
16/05/23	Cantor Fitzgerald Lowers Price Target on Seelos Therapeutics to $2 From $3, Maintains Overweight Rating	MT
24/03/23	Benchmark Adjusts Price Target on Seelos Therapeutics to $4 From $6, Maintains Buy Rating	MT

Seelos Therapeutics, Inc. Stock

Stocks

SEELQ

US81577F4063

Biotechnology & Medical Research

Valuation: Seelos Therapeutics, Inc.

Chart: Seelos Therapeutics, Inc.

Latest news : Seelos Therapeutics, Inc.

Analysts' recommendations: Seelos Therapeutics, Inc.

Press Releases: Seelos Therapeutics, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Seelos Therapeutics, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

22/11/24	Seelos Therapeutics : Late Filing Notice Form NT 10 Q	PU
25/10/24	Seelos Therapeutics : Announces Second Postponement of its Annual Meeting of Stockholders Form 8 K	PU
25/10/24	Seelos Announces Second Postponement of its Annual Meeting of Stockholders	PR
15/10/24	Seelos Therapeutics : Announces Notice of Delisting from Nasdaq and Transfer of Listing to Over the Counter Market Form 8 K	PU
15/10/24	Seelos Therapeutics Announces Notice of Delisting from Nasdaq and Transfer of Listing to Over-the-Counter Market	PR

Current year	0		0.01
1 year	0		0.01
3 years	0		6,374.41
5 years	0		10,713.61
10 years	0		28,761.63

Manager	Title	Age	Since
Raj Mehra CEO	Chief Executive Officer	66	01/01/2019
Michael Golembiewski DFI	Director of Finance/CFO	54	01/09/2021
Gopal Krishna CTO	Chief Tech/Sci/R&D Officer	-	-

Date	Insider	Type	Main position	Quantity	% Market Cap.
29/02/24	Michael Golembiewski	Free	Chief Financial Officer	417	0.0043%
12/01/24	Michael Golembiewski	Free	Chief Financial Officer	24,537	0.2505%
12/01/24	Raj Mehra	Free	Chief Executive Officer	70,383	0.7186%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SEELOS THERAPEUTICS, INC.	+9,900.00%	-.--%	-	-100.00%	136
ARGENX SE	-4.44%	-8.23%	+57.07%	+116.84%	56.98B
WUXI APPTEC CO., LTD.	+1.84%	+1.65%	+76.90%	+95.68%	53.58B
INSMED INCORPORATED	-3.35%	+1.97%	+17.67%	+457.55%	25.63B
BIONTECH SE	-1.81%	-3.06%	-20.07%	-15.24%	23.51B
WUXI BIOLOGICS (CAYMAN) INC.	+2.43%	+5.86%	+46.56%	+0.42%	19.43B
GENMAB A/S	-3.19%	0.00%	+33.99%	-26.87%	18.12B
PHARMAESSENTIA CORPORATION	-6.84%	+2.18%	+203.03%	+348.11%	16.46B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+8.74%	+10.46%	+47.66%	-	14.13B
EXELIXIS, INC.	-2.01%	+0.59%	+23.66%	+192.89%	14.35B
Average	+989.10%	+1.05%	+54.05%	+118.82%	24.22B
Weighted average by Cap.	-1.30%	+0.29%	+54.62%	+136.68%

	2022	2023
Net sales	-	2.2 1.93 1.78 1.64 3.12 210.28 3.17 21.28 8.34 103.26 8.27 8.09 357.69
Net income	-73.53M -64.33M -59.32M -54.89M -104M -7.02B -106M -710M -278M -3.45B -276M -270M -11.94B	-37.88M -33.14M -30.56M -28.28M -53.67M -3.62B -54.57M -366M -143M -1.78B -142M -139M -6.15B
Net Debt	4.59M 4.01M 3.7M 3.43M 6.5M 438M 6.61M 44.33M 17.38M 215M 17.23M 16.85M 745M	11.23M 9.83M 9.06M 8.38M 15.91M 1.07B 16.18M 109M 42.54M 526M 42.17M 41.25M 1.82B